tension

Small moleculeapproved

Approved

May 3, 1951

Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 7 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Dec 1, 1996 (NCT00748059)

Timeline

1950s

May 3, 1951
Pharmaceutical Associates — Earliest FDA Approval
May 3, 1951
Pharmaceutical Associates — Marketing Organization
May 3, 1951
Teligent Pharmaceuticals — NDA Secondary Org
May 3, 1951
Pharmaceutical Associates — NDA Secondary Org
May 3, 1951
Pharmaceutical Associates — NDA Organization

1980s

Aug 6, 1985
Mylan — Marketing Organization
Aug 6, 1985
PHARMOBEDIENT — NDA Secondary Org
May 13, 1988
Organon — Marketing Organization

1990s

Nov 6, 1991
Mylan — NDA Secondary Org
Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
Feb 24, 1998
Hospira — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

AcetylcholinesteraseINHIBITOR
ACHE inhibitor
- Acetylcholinesterase (ACHE) ↗

Combination products

enlon-plus
with atropine

Approval history

approvedPriority reviewMay 3, 1951

Chemistry & pharmacology

Loading structure…

SMILES

CC[N+](C)(C)c1cccc(O)c1

Mol. weight: 166.24 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Discontinued

Oral

Parenteral

Yes

Topical

Sources

Also known as

3-hydroxy-n,n-dimethyl-n-ethylanilinium
3-hydroxy-n,n-dimethyl-n-ethylanilinium
(3-hydroxyphenyl)dimethylethylammonium
(3-hydroxyphenyl)dimethylethylammonium
camsilon
edr
edr
edrophone chloride
edrophone chloride
edrophonium
edrophonium
edrophonium
edrophonium
edrophonium
edrophonium
edrophonium
edrophonium
edrophonium
edrophonium chloride
edrophonium chloride
edrophonium chloride
edrophonium chloride
edrophonium chloride preservative free
edrophonium chloride preservative free
edrophonium ion
edrophonium ion
enlon
enlon
enlon-plus
enlon-plus
ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium
ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium
n-ethyl-3-hydroxy-n,n-dimethylanilinium
n-ethyl-3-hydroxy-n,n-dimethylanilinium
n-ethyl-3-hydroxy-n,n-dimethylbenzenaminium
n-ethyl-3-hydroxy-n,n-dimethylbenzenaminium
reversol
reversol
tensilon
tensilon
tensilon preservative free
tensilon preservative free
tension
tension

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00748059	Phase 1	Dec 1, 1996	Vanderbilt University

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Vanderbilt University	Academic/Hospital	1	1	1	1996

1 organizations

Page 1 / 1

Marketing (10)

Organization	Org type	Relationship	Date
Hospira	For profit	MKTG	Feb 24, 1998
Mylan	For profit	MKTG	Aug 6, 1985
Mylan	For profit	NDA2	Nov 6, 1991
Organon	For profit	MKTG	May 13, 1988
PHARMOBEDIENT	For profit	NDA2	Aug 6, 1985
Pharmaceutical Associates	For profit	MKTG	May 3, 1951
Pharmaceutical Associates	For profit	NDA2	May 3, 1951
Pharmaceutical Associates	For profit	NDA	May 3, 1951
Teligent Pharmaceuticals	For profit	NDA2	May 3, 1951
Watson Pharmaceuticals	For profit	MKTG	—